Bench Side Story continues with Dr Michael Collins, a kidney transplant specialist at Royal Adelaide Hospital in South Australia.
He is the Principal Investigator of a trial called the BEST Fluids trial, which has recently been completed and showed which was the best treatment in terms of intravenous fluids to use for kidney transplant recipients.
Since he was a young child, Dr Collins, has been interested in kidney failure and kidney transplants in particular. His father was also a kidney specialist, and he used to sit by the phone when his father, was on call and ringing people who were being offered a kidney transplant. The joy in their voices through this interaction created a lasting and profound impact on Dr Collins. This carried through his career and today he continues to seek better outcomes for Kidney patients.
-
Next generation nanomedicine and radiopharmaceuticals to treat cancer
Finding better ways of treating cancer, aside from finding a cure, aim to provide a better quality of life for those who suffer from it.
Professor Thurecht’s work focuses on nanomedicine and spans across the Australian Institute for Bioengineering and Nanotechnology and the Centre for Advanced Imaging, at the University of Queensland in Australia.
-
Identification, characterisation and role of leader cells in ovarian cancer progression
Dr. Maree Bilandzic is a molecular cancer biologist dedicated to advancing the understanding and treatment of ovarian cancer (OC). Her research addresses critical gaps in OC treatment by investigating the mechanisms behind metastasis, chemotherapy resistance, and tumour recurrence. By utilising innovative methodologies and disease-representative models, Dr. Bilandzic has pioneered the identification and characterisation of leader cells (LCs)—a unique, stem-like subpopulation within tumours that plays a crucial role in OC progression.
-
Mechanisms of resistance to menin inhibitor therapy and Acute Myeloid Leukaemia
Dr Rithin Nedumannil (MBBS, MPH, FRACP, FRCPA) is a PhD candidate at the University of Melbourne, undertaking his doctoral studies in collaboration with the Cambridge Stem Cell Institute (Cambridge, UK) and the Peter MacCallum Cancer Centre (Melbourne, Australia). He is a clinical haematologist and haematopathologist with current appointments at Peter MacCallum Cancer Centre, the Royal Melbourne Hospital, Austin Health and Northern Health.
